These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 10915159)

  • 21. 3-Amino-2(5H)furanones as inhibitors of subgenomic hepatitis C virus RNA replication.
    Iannazzo D; Piperno A; Romeo G; Romeo R; Chiacchio U; Rescifina A; Balestrieri E; Macchi B; Mastino A; Cortese R
    Bioorg Med Chem; 2008 Nov; 16(21):9610-5. PubMed ID: 18835180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches.
    von Hahn T; Steinmann E; Ciesek S; Pietschmann T
    Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):63-79. PubMed ID: 20136590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent contributions of in vitro models to our understanding of hepatitis C virus life cycle.
    Régeard M; Lepère C; Trotard M; Gripon P; Le Seyec J
    FEBS J; 2007 Sep; 274(18):4705-18. PubMed ID: 17824957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C virus--biology, host evasion strategies, and promising new therapies on the horizon.
    Qureshi SA
    Med Res Rev; 2007 May; 27(3):353-73. PubMed ID: 16958135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular virology of hepatitis C].
    Moradpour D; Brass V; Gosert R; Wölk B; Blum HE
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2247-53. PubMed ID: 12564041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HCV/HIV co-infection therapy.
    Pietrandoni G
    Posit Aware; 2002; 13(2):32, 38. PubMed ID: 12004829
    [No Abstract]   [Full Text] [Related]  

  • 28. [Molecular epidemiology of chronic hepatitis C (HCV) virus].
    Nitkiewicz J
    Przegl Epidemiol; 2004; 58(3):413-21. PubMed ID: 15730005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma.
    De Mitri MS; Cassini R; Morsica G; Bagaglio S; Andreone P; Loggi E; Muratori P; Bernardi M
    J Viral Hepat; 2006 Sep; 13(9):574-81. PubMed ID: 16907843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hepatitis C: contemporary views on molecular biology of HCV].
    Adamek A
    Pol Merkur Lekarski; 1999 Jan; 6(31):53-6. PubMed ID: 10344159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro replication models for the hepatitis C virus.
    Sheehy P; Mullan B; Moreau I; Kenny-Walsh E; Shanahan F; Scallan M; Fanning LJ
    J Viral Hepat; 2007 Jan; 14(1):2-10. PubMed ID: 17212638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experimental models for hepatitis C viral infection.
    Boonstra A; van der Laan LJ; Vanwolleghem T; Janssen HL
    Hepatology; 2009 Nov; 50(5):1646-55. PubMed ID: 19670425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV and HCV co-infection: situation at six French university hospitals in the year 2000.
    Buffet-Janvresse C; Peigue-Lafeuille H; Benichou J; Vabret A; Branger M; Trimoulet P; Goria O; Laurichesse H; Abbed A; Verdon R; Bouvet E; Lafon ME; Dussaix E; Cormerais L; Dupon M; Henquell C; Josse A; Lagoutte P; Lariven S; LeGac S; Riachi G; Verdon R; Vittecoq D;
    J Med Virol; 2003 Jan; 69(1):7-17. PubMed ID: 12436472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture.
    Bartenschlager R
    Curr Opin Microbiol; 2006 Aug; 9(4):416-22. PubMed ID: 16814596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
    Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
    J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oligonucleotide-based therapeutic options against hepatitis C virus infection.
    Trepanier JB; Tanner JE; Alfieri C
    Antivir Ther; 2006; 11(3):273-87. PubMed ID: 16759043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
    McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM
    J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491
    [No Abstract]   [Full Text] [Related]  

  • 39. [Host factors involved in regulation of replication and pathogenesis of hepatitis C virus ].
    Moriisi K; Mori Y; Taguwa S; Matsuura Y
    Tanpakushitsu Kakusan Koso; 2009 Jun; 54(8 Suppl):940-6. PubMed ID: 21089521
    [No Abstract]   [Full Text] [Related]  

  • 40. [Should Hepatitis C be treated? Objectives of antiviral treatments in hepatitis C virus infection].
    Degos F
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S57-65. PubMed ID: 9161515
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.